ICER posts draft scoping document for the assessment of treatments for acute migraine

ICER

28 June 2019 - Document open to public comment until 19 July 2019

The Institute for Clinical and Economic Review has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value treatments for acute migraine, including: two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan); and a 5-HT1f agonist lasmiditan (Eli Lilly). 

All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder